GlaxoSmithKline signed an agreement that calls for MolMed, an Italian biotech company, to create a production process for an experimental gene treatment for ADA-SCID, also known as adenosine deaminase deficiency-severe combined immune deficiency or "bubble boy disease." The two-year deal is worth $7.7 million. The most common treatment for the disease is a bone marrow transplant, but even matched or related donor cells carry the risk of rejection.

Full Story:

Related Summaries